Pfizer also plans to make a $100 million equity investment in the Chinese biotechnolgoy company after the transaction closes, ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio. 3SBio ...

Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news. I’ve been a couples therapist for 30 years: Any of ...

Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared ...

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

3SBio will receive an upfront payment of $1.25B and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8B as well as tiered ...